#1 Clinical Trials Search in Europe

Bemnifosbuvir Hemisulfate

Bemnifosbuvir Hemisulfate is an investigational antiviral drug currently being studied in clinical trials for the treatment of COVID-19 and chronic hepatitis C virus (HCV) infection. These trials aim to evaluate the safety and efficacy of the drug in different patient populations, potentially offering new treatment options for these viral diseases.

Table of Contents

What is Bemnifosbuvir?

Bemnifosbuvir Hemisulfate, also known as BEM, AT-527, or RO7496998, is an investigational antiviral medication being studied for the treatment of COVID-19 and chronic hepatitis C virus (HCV) infection[1][2]. It is a direct-acting antiviral (DAA) drug, which means it directly targets the virus to prevent it from replicating in the body.

Bemnifosbuvir for COVID-19 Treatment

Bemnifosbuvir is currently being investigated as a potential treatment for COVID-19 in high-risk outpatients. A Phase 3 clinical trial is underway to evaluate its effectiveness and safety[1]. The study aims to determine if Bemnifosbuvir can:

  • Reduce the risk of hospitalization or death in COVID-19 patients
  • Decrease COVID-19 related complications
  • Reduce the need for medical visits related to COVID-19
  • Prevent symptom relapse
  • Reduce viral load and prevent viral rebound

The study focuses on high-risk individuals, including those who are:

  • 70 years of age or older
  • 55 years or older with certain risk factors (e.g., obesity, diabetes, cardiovascular disease, chronic lung disease)
  • 50 to 54 years old with two or more risk factors
  • 18 years or older with specific conditions (e.g., Down syndrome, sickle cell disease, immunocompromising conditions)

Bemnifosbuvir for Hepatitis C Treatment

In addition to its potential use for COVID-19, Bemnifosbuvir is also being studied as a treatment for chronic hepatitis C virus (HCV) infection[2]. A Phase 2 clinical trial is evaluating the safety and efficacy of Bemnifosbuvir in combination with another antiviral drug called Ruzasvir (RZR) for patients with chronic HCV.

The main goals of this study are to:

  • Assess the safety and tolerability of the BEM + RZR combination
  • Evaluate the effectiveness of the treatment in achieving a sustained virologic response (SVR), which indicates that the virus is no longer detectable in the blood
  • Determine the proportion of patients who experience treatment failure or relapse

How Bemnifosbuvir Works

Bemnifosbuvir is a nucleotide analog, which means it mimics the building blocks of viral genetic material. When the virus tries to replicate, it incorporates Bemnifosbuvir into its genetic code, disrupting the replication process and preventing the virus from multiplying[1][2].

How Bemnifosbuvir is Administered

Bemnifosbuvir is taken orally in tablet form. In the COVID-19 study, the maximum daily dose is 1100 mg, with a total treatment period of up to 5 days[1]. For the hepatitis C study, the maximum daily dose is 550 mg, with a longer treatment period of up to 8 weeks[2].

Potential Side Effects

As Bemnifosbuvir is still in clinical trials, the full range of potential side effects is not yet known. The ongoing studies are carefully monitoring participants for any adverse events or serious adverse events that may occur during treatment[1][2].

Ongoing Research

Bemnifosbuvir is currently being studied in clinical trials and is not yet approved for general use. The results of these studies will help determine its safety and effectiveness in treating COVID-19 and chronic hepatitis C. If successful, Bemnifosbuvir could become an important tool in the fight against these viral infections[1][2].

Aspect COVID-19 Trial Hepatitis C Trial
Study Phase Phase 3 Phase 2
Study Design Randomized, Double-Blind, Placebo-Controlled Open-Label
Primary Objective Evaluate efficacy in reducing hospitalization or death Evaluate safety and efficacy (SVR12)
Patient Population High-risk COVID-19 outpatients Chronic HCV patients (DAA-naïve)
Treatment Bemnifosbuvir vs Placebo Bemnifosbuvir + Ruzasvir
Primary Endpoint All-cause hospitalization or death through Day 29 SVR12 (sustained virologic response at 12 weeks post-treatment)
Key Inclusion Criteria Positive SARS-CoV-2 test, mild/moderate symptoms, high-risk factors Chronic HCV, DAA-naïve, absence of cirrhosis or compensated cirrhosis
Key Exclusion Criteria Severe COVID-19, recent hospitalization, certain medications HBV/HIV co-infection, decompensated liver disease, prior HCV DAA exposure

FAQ

  • What is Bemnifosbuvir Hemisulfate? Bemnifosbuvir Hemisulfate is an investigational antiviral drug being studied for the treatment of COVID-19 and chronic hepatitis C virus (HCV) infection. It is also known by its product code AT-527.
  • What are the main objectives of the COVID-19 clinical trial? The main objective of the COVID-19 clinical trial is to evaluate the efficacy of Bemnifosbuvir compared to placebo in reducing all-cause hospitalization or death in high-risk COVID-19 outpatients receiving only supportive care.
  • Who is eligible for the COVID-19 clinical trial? Eligible participants include adults with mild to moderate COVID-19 symptoms, a positive SARS-CoV-2 test within 5 days of randomization, and at least one high-risk factor such as being 70 years or older, or having certain medical conditions like obesity, diabetes, or cardiovascular disease.
  • What is the purpose of the hepatitis C clinical trial? The hepatitis C clinical trial aims to assess the safety and efficacy of a combination of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection who have not been previously treated with direct-acting antivirals.
  • How is the effectiveness of the treatments measured in these trials? In the COVID-19 trial, effectiveness is primarily measured by the reduction in hospitalization or death. For the hepatitis C trial, the main measure of effectiveness is the proportion of patients achieving sustained virologic response (undetectable virus levels) 12 weeks after treatment completion.

Ongoing Clinical Trials on Bemnifosbuvir Hemisulfate

  • Study on the Effectiveness and Safety of Bemnifosbuvir for High-Risk COVID-19 Patients

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Latvia The Netherlands Romania Spain Sweden

  • Study on the Safety and Effectiveness of Bemnifosbuvir and Ruzasvir for Patients with Chronic Hepatitis C

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Romania Spain

Glossary

  • Bemnifosbuvir Hemisulfate: An investigational antiviral drug being studied for the treatment of COVID-19 and chronic hepatitis C virus infection.
  • Placebo: A substance that has no active ingredients and is used as a control in clinical trials to test the effectiveness of a drug.
  • Sustained Virologic Response (SVR): A measure used in hepatitis C treatment, indicating that the virus is no longer detectable in the blood after treatment completion.
  • Direct-Acting Antiviral (DAA): A type of medication that directly interferes with the hepatitis C virus's ability to multiply and spread.
  • Randomization: The process of randomly assigning participants to different treatment groups in a clinical trial to reduce bias.
  • Efficacy: The ability of a treatment to produce the desired result under ideal conditions in a clinical trial.
  • Hepatitis C Virus (HCV): A virus that causes inflammation of the liver, potentially leading to serious liver damage if left untreated.
  • Cirrhosis: Severe scarring of the liver, often caused by long-term liver diseases such as chronic hepatitis C.
  • Child-Pugh Score: A scoring system used to assess the severity of chronic liver disease and cirrhosis.
  • Virologic Failure: The inability to achieve or maintain suppression of viral replication during or after treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bemnifosbuvir-for-high-risk-covid-19-patients/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bemnifosbuvir-and-ruzasvir-for-patients-with-chronic-hepatitis-c/